Results 51 to 60 of about 2,265 (188)

Group 2 Innate Lymphoid Cells in Respiratory Allergic Inflammation [PDF]

, 2019
Millions of people worldwide are suffering from allergic inflammatory airway disorders. These conditions are regarded as a consequence of multiple imbalanced immune events resulting in an inadequate response with the exact underlying mechanisms still ...
Duerr, Claudia U., Fritz, Jörg H., Helfrich, Sofia, Mindt, Barbara C.   +3 more
core   +1 more source

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Respiratory Research, 2020
Background Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that have broader effects on airway inflammation, and that provide greater improvements in asthma outcomes than currently approved biologics and ...
Andrew Menzies-Gow, Gene Colice, Janet M. Griffiths, Gun Almqvist, Sandhia Ponnarambil, Primal Kaur, Gennaro Ruberto, Karin Bowen, Åsa Hellqvist, May Mo, Esther Garcia Gil   +10 more
doaj   +1 more source

Tezepelumab in Adults with Uncontrolled Asthma

New England Journal of Medicine, 2017
In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose ...
Jonathan, Corren, Jane R, Parnes, Liangwei, Wang, May, Mo, Stephanie L, Roseti, Janet M, Griffiths, René, van der Merwe   +6 more
openaire   +2 more sources

Tezepelumab treatment in severe asthma with recurrent chronic rhinosinusitis with nasal polyps: Case series

Journal of Allergy and Clinical Immunology: Global
Background: Tezepelumab is a human IgG2 mAb that inhibits thymic stromal lymphopoietin (TSLP) and is approved for treatment of severe asthma. Bronchial asthma, usually a type 2 inflammatory disease, often co-occurs with chronic rhinosinusitis with nasal ...
Yoshiro Kai, MD, PhD
doaj   +1 more source

The Influence of US Drug Price Dynamics on Cost-Effectiveness Analyses of Biologics [PDF]

, 2022
Objectives: This study aimed to evaluate the influence of drug price dynamics in cost-effectiveness analyses. Methods: We evaluated scenarios involving typical US drug price increases during the exclusivity period and price decreases after the loss of ...
Campbell, Jon R., Kogut, Stephen Jon, Pearson, Steven D.   +2 more
core   +1 more source

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study

Journal of Asthma and Allergy, 2021
Jonathan Corren,1 Martin Karpefors,2 Åsa Hellqvist,3 Jane R Parnes,4 Gene Colice5 1Departments of Medicine and Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; 2Data Science and AI, AstraZeneca ...
Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G   +4 more
doaj  

Biologics in severe asthma:A pragmatic approach for choosing the right treatment for the right patient [PDF]

, 2023
The development of monoclonal antibody therapies targeting specific components of the pathways relevant to asthma pathophysiology has revolutionized treatment of severe asthma both in adults and children and helped to further unravel the heterogeneity of
Bjermer, Leif, Diamant, Zuzana, Hanania, Nicola A., Jesenak, Milos, Rogers, Linda, Seys, Sven F.   +5 more
core   +1 more source

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study

Journal of Asthma and Allergy, 2021
Claire Emson,1 Jonathan Corren,2 Kinga Sałapa,3 Åsa Hellqvist,4 Jane R Parnes,5 Gene Colice6 1Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca ...
Emson C, Corren J, Sałapa K, Hellqvist Å, Parnes JR, Colice G   +5 more
doaj  

Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma

, 2019
Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma.
Bousquet, Jean, Brusselle, Guy, Buhl, Roland, Katsaounou, Paraskevi, Martinez, Rafael, Pfister, Pascal, Wahn, Ulrich   +6 more
core   +1 more source

Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy [PDF]

, 2023
The role of type 2 inflammation has been progressively associated with many diseases, including severe asthma, atopic dermatitis, nasal polyposis, eosinophilic granulomatosis with polyangiitis, and, recently, eosinophilic esophagitis.
Bagnasco D., Braido F., Candeliere M. G., Giannini E., Marabotto E., Passalacqua G., Savarino E. V., Yacoub M. -R.   +7 more
core   +1 more source